Matthew Ettleson is an Endocrinology/Metabolic physician affiliated with University of Chicago. OpenAlex indexes 45 publications with 375 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5841 S Maryland Ave # Mc1027
Chicago, IL 606371443
Telephone
773-702-6227Registry record last updated 16 Jun 2019.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Acella Pharmaceuticals, LLCProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
76.7%GLP-1 receptor agonist31.6%Trulicity35%Ozempic30%Rybelsus19%Mounjaro17%Part D<11 patientsInsulin Analog19.8%Lantus Solostar75%Humalog Kwikpen U-10025%Part D<11 patients+ 4 more classes in this area
Hormonal (systemic)
15.3%l-Thyroxine8%Levothyroxine Sodium100%Part D<11 patientsThyroid Hormone Synthesis Inhibitor7.3%Methimazole100%Part D<11 patientsCardiovascular
8%Statin8%Atorvastatin Calcium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2026 per NIH RePORTER. The latest:
- Redefining and Improving Hypothyroidism Care Using Real-World Data
University of Chicago
FY2026$169,763K23DK138262 - Redefining and Improving Hypothyroidism Care Using Real-World Data
University of Chicago
FY2025$172,003K23DK138262
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Distribution of Outpatient Visits Among Adults With Hypothyroidism: NAMCS 2010-2019
AACE Endocrinology and Diabetes
2026 - Treatment of Hypothyroidism That Contains Liothyronine is Associated With Reduced Risk of Dementia and Mortality
The Journal of Clinical Endocrinology & Metabolism
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Everett Vokes, MD
University of Chicago
Ralph Weichselbaum, MD
University of Chicago
Mary Rinella, MD
University of Chicago
Hedy Kindler, MD
University of Chicago
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”